Information  X 
Enter a valid email address

Summit Corporation PLC (SUMM)

  Print      Mail a friend

Monday 19 September, 2011

Summit Corporation PLC

Research Update: New data presented at ICAAC co...

Summit Corporation plc
("Summit" or "the Company")


Oxford, UK, 19 September 2011, Summit (AIM: SUMM), a UK drug discovery company,
announces that it is presenting new positive data from its antibiotic programme
targeting infections caused by the 'superbug' Clostridium difficile at the 51st
annual Interscience Conference on Antimicrobial Agents and Chemotherapy
('ICAAC') being held in Chicago, US, between 17 and 20 September 2011.

ICAAC is the premier meeting on infectious diseases and anti-microbial agents
and brings together selected world-renowned scientists in the field to present
their latest research.

Commenting on the news, Summit's Chief Scientific Officer, Richard Storer,
DPhil, said:
"C. difficile infection ('CDI') is a serious medical issue that remains poorly
treated.  Summit's programme, which has been supported by a prestigious grant
from the Wellcome Trust, has identified a novel class of antibiotics that have
the ideal profile to address the key clinical issues.

"The data being presented at ICAAC highlight our preclinical development
candidate SMT 19969 and includes the reporting of new positive results from non-
clinical efficacy studies in the gold standard disease model in which it showed
superiority over the antibiotic vancomycin, the current standard of care.
 Summit is very excited about the prospects for SMT 19969 as we believe it has
the profile to become the front-line antibiotic of choice to treat CDI."

The data are being presented by Summit and two key opinion leaders in the field
who have been collaborating with the Company in the development of the
programme.  Details of the presentations are as follows:

"SMT19969: A novel antibiotic for C. difficile infection; C. difficile growth
inhibition, spectrum of activity and resistance development"
Presenter: Richard Vickers, PhD, Associate Director and Principal Investigator,
Monday, 19 September 2011 at 11:15-13:15 CDT
Presentation number: B-1194, session 167

"Efficacy of SMT19969 and SMT21829 in a hamster model of Clostridium difficile
associated disease"
Presenter: William Weiss, Director of Preclinical Services, University of North
Texas Health Science Centre in Fort Worth, US
Monday, 19 September 2011 at 11:15-13:15 CDT
Presentation number: B-1195, session 167

"Efficacy of novel antimicrobial agent SMT19969 against simulated Clostridium
difficile infection in an in vitro human gut model"
Presenter: Professor Mark Wilcox, Consultant and Clinical Director of
Microbiology and Pathology, Leeds Teaching Hospitals NHS Trust, UK.
Monday, 19 September 2011 at 11:15-13:15 CDT
Presentation number: B-1193, session 167

SMT 19969: A targeted antibiotic for the treatment of C. difficile infection

C. difficile infection represents a serious medical issue in hospitals and long-
term care homes and there is growing concern about its spread to the wider
community.  The combined annual cost of care in Europe and North America is
estimated at over $7 billion.

The major clinical issue in treating CDI is preventing recurrent disease because
repeat episodes of infection are often more severe.  The severity of the disease
is also increasing due to infection caused by hypervirulent C. difficile strains
such as BI/NAP1/027.  The limited treatment options currently available are
failing to address these clinical challenges.

The presentations at ICAAC report the results from a series of non-clinical
efficacy studies, including those undertaken in a human gut model of CDI and the
gold standard in vivo disease model, to highlight how Summit's programme
addresses the key clinical challenges.

In summary the results show that Summit's preclinical development candidate, SMT
19969, has an unprecedented profile when compared to antibiotics that are
currently on the market to treat CDI.  SMT 19969 combines potent activity
against a comprehensive panel of C. difficile clinical isolates, including
hypervirulent, endemic and emerging strains, with exceptionally high levels of
antibacterial selectivity. This selectivity means there is a lack of disruption
to the healthy gut bacteria and this is important in naturally preventing
recurrence of CDI and improving the prognosis for patients.

New data generated from studies conducted in the gold standard in vivo disease
model show that SMT 19969 is superior in treating CDI, including infection by
the hypervirulent BI/NAP1/027 strain, compared to the current standard of care

In addition the compound is targeted exclusively to the site of infection in the
GI tract, shows exceptionally low levels of resistance development and has an
excellent safety profile.

Summit's programme is supported by a Seeding Drug Discovery Award from the
Wellcome Trust and the programme recently achieved a further research milestone
following nomination of SMT 19969 as the preclinical development candidate.  SMT
19969 remains on-target to commence human clinical trials in Q3 2012.

The presentations are available on request

                                    - END -

For more information, please contact:


 Barry Price, PhD,

 Richard Pye, PhD                             Tel: +44 (0)1235 443 951

 Singer Capital Markets (Nominated Adviser)

 Shaun Dobson / Claes Spång                   Tel: +44 (0)20 3205 7500

 Peckwater PR

 Tarquin Edwards                              Tel: +44 (0)7879 458 364

Notes to Editors

About Summit
Summit is an Oxford, UK based drug discovery company with an innovative
technology platform called Seglins for the discovery of new medicines, a
portfolio of drug programme assets and a commercial strategy of signing multiple
early-stage deals.

Seglin(TM)  technology is using new chemistry to access biological drug targets
that cannot be exploited by conventional drug discovery approaches.  Summit's
internal research is currently focussed in high-value therapy areas and the
Company will further exploit the technology's wider potential through strategic
alliances.  Summit's programme portfolio consists of a number of drug programmes
targeting high-value areas of unmet medical need including Duchenne Muscular
Dystrophy and C. difficile infection.

Summit's commercial strategy focuses on signing multiple early-stage drug
programme and technology platform deals that generate upfront cash, transfer
development costs from the Company, and retain valuable upside potential.

Summit is listed on the AIM market of the London Stock Exchange and trades under
the ticker symbol SUMM.  Further information is available

 Forward Looking Statements
This document contains "forward-looking statements" within the meaning of the
U.S. Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as "anticipates", "intends", "plans",
"seeks", "believes", "estimates", "expects" and similar references to future
periods, or by the inclusion of forecasts or projections. Forward-looking
statements are based on the Company's current expectations and assumptions
regarding our business, the economy and other future conditions. Because
forward-looking statements relate to the future, by their nature, they are
subject to inherent uncertainties, risks and changes in circumstances that are
difficult to predict. The Company's actual results may differ materially from
those contemplated by the forward-looking statements. The Company cautions you
therefore that you should not rely on any of these forward-looking statements as
statements of historical fact or as guarantees or assurances of future
performance. Important factors that could cause actual results to differ
materially from those in the forward-looking statements and regional, national,
global political, economic, business, competitive, market and regulatory

This announcement is distributed by Thomson Reuters on behalf of 
Thomson Reuters clients. The owner of this announcement warrants that: 
(i) the releases contained herein are protected by copyright and 
    other applicable laws; and 
(ii) they are solely responsible for the content, accuracy and 
     originality of the information contained therein. 
Source: Summit Corporation PLC via Thomson Reuters ONE